Correspondence Letter by Vos et al Regarding Article, “Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevent

We read with interest the article by Mora and colleagues,1 who are well supported when stating that “statins had not been found to reduce total or coronary mortality in women, men, or combined for primary prevention ” but suggest that their Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study indicates differently. We respectfully disagree. The article gives no data about cardiovascular mortality, which for men and women combined differed by only 8 (author’s response to Ridker and Glynn2; corresponding P0.37). In women specifically, calculating from combined data in Table 3 in the article by Mora et al,1 there would have been 10 cardiovascular deaths on rosuvastatin versus 13 on placebo, which would generate a P value of 0.51. The infarct and stroke findings were also not different in women after 6500 on-statin years. The only significant benefit in women in any of the 5 primary en